DelMar Pharma

DMPI NASDAQ
0.7646
-0.0653
-7.87%
Opening 13:06 08/19 EDT
Open
0.8400
Prev Close
0.8299
High
0.8400
Low
0.7500
Volume
322.09K
Avg Vol (3M)
769.68K
52 Week High
8.50
52 Week Low
0.7500
% Turnover
8.39%
Market Cap
2.93M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers DelMar Pharma DMPI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
MORE >

Recently

Name
Price
%Change